In another sign of the times, contestants on the wholesome, long-running game show Jeopardy have been challenged to answer questions about drugs like marijuana and LSD on at least three occasions in the past several weeks.
And, shocker: professional sports gambler James Holzhauer, who’s on the second-longest winning streak in the game’s history, got all three questions right.
Host Alex Trebek asked contestants on April 9 to name the “bitter buds” used for flavoring that are part of the cannabaceae family alongside marijuana. The first contestant to hit the buzzer guessed it was hemp. (His answer was initially deemed incorrect but he was later given credit by the show’s judges because the non-psychoactive cannabis cousin is indeed used to flavor some beers.)
Check out this Jeopardy question from last night about the relationship between marijuana and beer. pic.twitter.com/0cKUhYEleR
— Tom Angell 🌳📰 (@tomangell) April 10, 2019
Holzhauer swooped in with the more obvious answer, hops. Researchers recently discovered that millions of years ago, marijuana and hops were genetically much closer—more like sisters than cousins—but they evolved to become more genetically distinct.
On April 22, Trebek said “Bubba Kush” on national television.
— Tom Angell 🌳📰 (@tomangell) April 22, 2019
“On Jan. 1, 2014 in Denver, 1/8 ounce of Bubba Kush was the USA’s first legal sale of this for recreational purchases,” the host said.
Again, Holzhauer was on it and quickly answered “marijuana” for a cool $800.
But Holzhauer’s drug knowledge isn’t limited to cannabis. One of the $2,000 challenges on a recent episode was to identify the first part of the name of a “well-known hallucinogen” that ends “acid diethylamide.” The contestant said “lysergic,” as in LSD.
James Holzhauer correctly answered a Jeopardy question about LSD this week. pic.twitter.com/5mDF4QtF9A
— Tom Angell 🌳📰 (@tomangell) May 3, 2019
While Trebek has a reputation as the family friendly face of one of the country’s longest-running game shows, he and the show’s producers are clearly not shy about incorporating drug questions into the show.
And The A.V. Club recently revealed that while Jeopardy bans contestants from wagering certain naughty sums like $69 and $666, as well as numbers associated with white supremacist groups, it’s totally fine to bet $420.
Trebek, in fact, has some personal experience with marijuana, albeit during an accidental encounter. In the 1970s, Trebek visited a friend in California to have dinner and let his chocolate craving get the best of him. Seeing a plate of brownies, he dove head first and unknowingly consumed half a dozen hash-infused treats in one sitting.
“I love brownies—I’m a chocoholic—and I didn’t realize that they were hash brownies,” he told The Daily Beast in 2017. “And… whoa. That threw me for a loop.”
“The dinner party was on a Friday, and I was not able to leave that house until Sunday afternoon,” Trebek said. “I spent the next day and a half in bed. It was not a good trip, and I have not done any of that stuff since!”
UPDATE: After this story was published, Holzhauer weighed in on Twitter:
If there’s no room for me on the VGK analytics team, maybe I can have a career as a counterculture icon. https://t.co/XkTuH0nBp7
— James Holzhauer (@James_Holzhauer) May 12, 2019
Photo courtesy of Jeopardy!
Americans Want CBD Available Over-The-Counter, Poll Finds
A majority of Americans familiar with cannabidiol (CBD) say it should be available as an over-the-counter drug and that the compound has multiple health benefits, according to a Gallup survey released on Friday.
The CBD craze emerged from the marijuana reform movement and escalated following the passage of the 2018 farm bill, which federally legalized hemp and its derivatives including CBD. The survey, which involved 1,017 phone interviews conducted from May 15-30, offers some insight into the substance’s widespread appeal.
Thirty-nine percent of Americans overall said that people should be able to access CBD as an over-the-counter drug, with 21 percent saying a prescription should be required. Thirty-six percent of respondents said they weren’t familiar with the non-intoxicating compound.
But when Gallup asked people who said they were familiar with CBD the same question, 61 percent said that CBD should be over-the counter and 33 percent said it should be available for those with a prescription.
Participants were also asked to rate their familiarity with CBD. Fourteen percent said they were “very familiar,” 33 percent said they were “somewhat familiar,” 17 percent said they were “not too familiar” and 36 percent said they were “not familiar at all.”
Again zeroing in on those who said they were familiar with CBD, Gallup asked what they thought about its therapeutic value.
Nine-out-of-ten respondents agreed that CBD does have health benefits. Breaking that down, 33 percent said it has “a lot of benefits,” 45 percent said it has “some benefits” and 14 percent said it has “only a few benefits.” Only four percent said it has “no benefits” and three percent didn’t have an opinion.
“The CBD-oil arena is extremely active right now, including medical research into its benefits, state legislation governing its sale, federal legislation encouraging its production and corporate investment growing in the business,” Gallup wrote. “Although medical research has a long way to go to investigate all of the claims made about CBD, half of Americans already believe it has at least some medical value, and that percentage is likely to grow as more become familiar with the product.”
The commercial interest in CBD is explosive, with lawmakers and industry stakeholders putting pressure on federal agencies like the Food and Drug Administration (FDA) to streamline the regulatory process to provide for the compound’s lawful marketing in the food supply and as health supplements.
But even as the government develops those regulations, companies are wasting no time, flouting the FDA and putting CBD in everything from pricey lattes to Carl’s Jr. burgers. At the same time, CBD’s medical value has been strongly established; the FDA approved a CBD drug last year for the treatment of certain forms of epilepsy.
Gallup also released a separate survey on Thursday that explored the various reasons Americans support or opposed broader marijuana legalization.
Photo courtesy of Kimzy Nanney/Unsplash.
Oakland Marijuana Shop Flooded With Questions About Psilocybin Mushrooms After Decriminalization Vote
A vote to decriminalize psilocybin mushrooms and other psychedelics in Oakland has left some residents confused about whether the substances have become commercially available.
Debby Goldsberry, CEO of Magnolia Wellness, told Marijuana Moment that her licensed marijuana shop has been “receiving calls from our members and interested community members, wondering if the dispensary was or would carry these products.”
While the City Council voted unanimously last week in favor of a resolution that bars the use of “any city funds or resources to assist in the enforcement of laws imposing criminal penalties” against adults who using and possessing the plants and fungi, the measure specifically does not allow for their legal sale.
“Selling mushrooms would violate both our local and state licenses, and it would put us squarely in the crossfire of federal laws that treat these plant medicines as felonies,” Goldsberry said. “Magnolia Wellness, while appreciating their medicinal value, would never put our company, our member base or those in the community who depend on us for support at risk in order to provide medicinal mushrooms.”
Further, the shop’s staff doesn’t “have the experience of expertise to advise people on the use of psychedelic plant medicines,” she said.
Confusion over the distinction between decriminalization and commercial legalization isn’t confined to Oakland, or psychedelics laws for that matter.
A separate successful campaign to decriminalize psilocybin mushrooms in Denver last month was complicated by voters conflating the policy change with broader legalization. Kevin Matthews, campaign director of Decriminalize Denver, made education about the difference between the two policy reforms a cornerstone of the group’s outreach efforts.
“We spent a lot of time talking to people on the ground and letting them know that in terms of decriminalization, this is the kind of thing that’s simply going to keep people out of jail for using substances,” Matthews told Marijuana Moment. “I think it’s one thing we did a decent thing of was really letting people that you can’t go buy this at a dispensary.”
But whereas Decriminalize Denver spent months educating the public about their proposal as they collected signatures to place the measure on the ballot, the Oakland resolution was introduced and voted on in relatively short order.
That, Matthews said, likely contributed to misunderstandings about the policy implications. Another factor may be that the resolution’s sponsor in Oakland indicated just before the vote that legalization and regulated sales could follow.
“Now we have to agree on what’s being regulated and identify a pathway for distribution and sales,” Councilmember Noel Gallo told Marijuana Moment on the day his measure was approved. “Like with marijuana, we have to establish a process.”
But that plan may run up against resistance, including from reform-minded allies.
“I think that in terms of Oakland, it’s up to them to make it very clear that people can’t go buy this right now,” Matthews said. “And I don’t think anyone should be able to in a recreational setting like that.”
“I think it’s important for people to keep in mind that this is a people-powered movement, not a profit-powered movement. We have some time before we should even start considering any kind of recreational sales,” he said. “That could derail the whole damn movement.”
Decriminalize Nature, the campaign behind Oakland’s decriminalization victory, told Marijuana Moment that it does not support commercializing the plant-and fungi-based substances.
As an amendment attached to the resolution itself states, the measure “does not authorize or enable any of the following activities: commercial sale or manufacturing of these plants and fungi.”
Photo courtesy of Wikimedia/Mädi.
Spray Marijuana Mist On North Korea And Iran To Solve Nuclear Crisis, C-SPAN Caller Says
Katherine from New Hampshire has a novel idea to stave off nuclear war: fly over sites where the weapons are being developed and release a marijuana mist so that the workers will “chill out” and lose interest in creating the missiles.
During an open phone segment of C-SPAN’s Washington Journal on Wednesday, the viewer laid out her vision for world peace to a visibly amused Pedro Echevarria, host of the program.
“I have a comment, and I don’t know how it could be done, but I was thinking we could spray a marijuana-Prozac or peace-happy-friendly chemical mist over sites in Iran and North Korea, where they’re working to produce nuclear weapons,” she said. “And the mist would cause the workers at these sites in Iran and North Korea to chill out and become less interested in making nuclear missiles.”
“The world needs to relax and take deep breaths and be into good days instead of destruction and death, and that’s what they should be talking about,” she said.
Echevarria declined to comment on the proposal and turned to the next caller, who did not follow up about the cannabis chemtrail idea and instead chatted about socialism.
Photo courtesy of Wikimedia.